Literature DB >> 18020930

Biological agents in head and neck cancer.

Paolo Bossi1, Laura D Locati, Lisa Licitra.   

Abstract

Survival of head and neck cancer (HNC) patients has not dramatically improved over the last 30 years, despite the advances in surgical techniques, chemotherapeutic agents and radiotherapy treatment planning and definition. Different studies in molecular biology of HNC have been carried out, providing useful results for clinical application. HNC usually includes malignant tumors arising from mucosa of the upper aerodigestive tract, from nasopharynx to larynx/trachea, while salivary gland and thyroid cancers are less frequently listed in this classification. In this review, we chose to provide a comprehensive review of the role of biological agents in head and neck subsites. Molecular characteristics and treatment-relevant signaling pathways will be briefly discussed along with the results of the more recent clinical studies that include biological agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18020930     DOI: 10.1586/14737140.7.11.1643

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  1 in total

1.  A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.

Authors:  Glen C MacDonald; Michèle Rasamoelisolo; Joycelyn Entwistle; Jeannick Cizeau; Denis Bosc; Wendy Cuthbert; Mark Kowalski; Maureen Spearman; Nick Glover
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.